GLP-1 vs GIP vs glucagon
GLP-1, GIP and glucagon are distinct peptide hormones involved in metabolic regulation. Although their signalling pathways interact, each hormone is produced predominantly by different cell populations, activates its own receptor and performs different physiological functions.
GLP-1 and GIP are the two principal incretin hormones and help coordinate the metabolic response to food. Glucagon is produced primarily by pancreatic alpha cells and has a major role in maintaining glucose availability, particularly through its actions on the liver.
Understanding these differences is particularly important when examining newer compounds designed to activate two or three of these receptor systems simultaneously.
Comparison table
| Feature | GLP-1 | GIP | Glucagon |
|---|---|---|---|
| Full name | Glucagon-like peptide-1 | Glucose-dependent insulinotropic polypeptide | Glucagon |
| Principal source | Intestinal L cells | Intestinal K cells | Pancreatic alpha cells |
| Main receptor | GLP-1 receptor (GLP-1R) | GIP receptor (GIPR) | Glucagon receptor (GCGR) |
| Hormone category | Incretin | Incretin | Pancreatic hormone |
| Insulin-related effect | Enhances glucose-dependent insulin secretion | Enhances glucose-dependent insulin secretion | Primarily regulates glucose availability rather than acting as an incretin |
| Major metabolic role | Incretin, gastrointestinal and appetite-related signalling | Incretin and nutrient-related metabolic signalling | Hepatic glucose and broader metabolic regulation |
| Example related compound | Semaglutide | Tirzepatide targets GIPR and GLP-1R | Retatrutide includes GCGR activity |
The table describes broad physiological differences. Pharmaceutical receptor agonists are engineered molecules and should not be considered equivalent to the naturally occurring hormones whose receptors they target.
Insulin-related signalling
GLP-1 and GIP can both enhance insulin secretion from pancreatic beta cells when circulating glucose is elevated. This glucose-dependent action is a defining characteristic of their incretin biology.
Glucagon has a different principal relationship with glucose regulation. Rather than functioning as an incretin, glucagon signals predominantly through the liver to increase glucose availability when required.
Insulin, GLP-1, GIP and glucagon therefore participate in an interconnected regulatory network rather than operating independently.
Appetite-related research
GLP-1 signalling has a well-established connection with neural pathways involved in satiety and food intake. GLP-1 receptors are expressed within brain regions involved in appetite regulation, and gastrointestinal GLP-1 contributes to gut-brain communication following nutrient intake.
GIP receptors are also present within the nervous system, and GIP-related appetite and energy-balance signalling remains an active research area.
Glucagon-receptor activation has additionally been investigated in relation to energy balance and food intake. However, the appetite effects of compounds simultaneously targeting several receptors cannot be attributed to one pathway without appropriate experimental evidence.
Metabolic role
GLP-1 helps coordinate the post-meal response through glucose-dependent insulin secretion, regulation of glucagon, gastrointestinal signalling and neural pathways associated with satiety.
GIP is released following nutrient intake and contributes strongly to glucose-dependent insulin secretion while also participating in signalling involving adipose tissue and other metabolic systems.
Glucagon becomes particularly important when glucose availability must be maintained. Its actions on the liver promote processes including glycogenolysis and gluconeogenesis.
The three pathways consequently provide complementary mechanisms for regulating nutrient handling and energy metabolism.
Example compounds interacting with each pathway
Semaglutide is a long-acting GLP-1 receptor agonist. It activates GLP-1R but does not reproduce every characteristic of short-lived endogenous GLP-1 signalling.
Tirzepatide activates both GIP and GLP-1 receptors and is therefore described as a dual GIP/GLP-1 receptor agonist.
Retatrutide has been developed as a triple receptor agonist targeting GIP, GLP-1 and glucagon receptors.
These compounds should not be treated as interchangeable. Their molecular structures, receptor profiles and pharmacokinetic properties differ, meaning evidence obtained with one compound cannot automatically be transferred to another.
What is a triple agonist?
A triple agonist is a molecule designed to activate three different receptor systems.
Within metabolic peptide research, the term commonly refers to simultaneous agonism of the GIP, GLP-1 and glucagon receptors. Instead of administering the three natural hormones, researchers can design a single peptide capable of interacting with all three receptors.
The relative strength of activity at each receptor is an important characteristic. A triple agonist does not necessarily activate GLP-1R, GIPR and GCGR equally, and changing this balance can alter its overall pharmacology.
Retatrutide and multi-receptor research
Retatrutide is an investigational peptide engineered to activate GIP, GLP-1 and glucagon receptors.
Its design allows researchers to investigate the combined effects of three metabolic signalling pathways within a single molecule. This distinguishes it from semaglutide, which targets GLP-1R, and tirzepatide, which targets GIPR and GLP-1R.
The glucagon component is particularly important when interpreting retatrutide research because glucagon-receptor signalling has physiological effects that differ substantially from incretin signalling.
Results observed with retatrutide therefore represent the pharmacology of the complete triple-agonist molecule and should not be described simply as GLP-1, GIP or glucagon effects individually.
Frequently asked questions
What is the main difference between GLP-1, GIP and glucagon?
GLP-1 and GIP are incretin hormones released predominantly from the gastrointestinal tract following nutrient intake. Glucagon is produced primarily by pancreatic alpha cells and has a major role in maintaining glucose availability through hepatic signalling.
Are GLP-1 and GIP the same hormone?
No. They are separate peptides that activate different receptors, although both can enhance glucose-dependent insulin secretion.
Is glucagon an incretin?
No. GLP-1 and GIP are the two principal recognised incretin hormones. Glucagon has a different physiological role.
Which receptors does semaglutide activate?
Semaglutide is a GLP-1 receptor agonist.
Which receptors does tirzepatide activate?
Tirzepatide is a dual agonist targeting GIP and GLP-1 receptors.
Which receptors does retatrutide activate?
Retatrutide is designed to activate GIP, GLP-1 and glucagon receptors.
Why combine several receptor pathways?
Multi-receptor research investigates whether coordinated activation of complementary metabolic pathways produces biological effects different from targeting a single receptor. The resulting pharmacology depends on the exact molecule and its relative activity at each receptor.
Does a triple agonist contain GLP-1, GIP and glucagon?
Not necessarily. A triple agonist can be a single engineered molecule designed to activate all three receptors rather than a mixture of the three endogenous hormones.
Scientific references
Scientific literature comparing GLP-1, GIP and glucagon includes extensive research into incretin physiology, pancreatic endocrine signalling, intestinal hormone secretion, hepatic glucose regulation and GLP-1R, GIPR and GCGR pharmacology. Research involving semaglutide, tirzepatide and retatrutide should be attributed to the individual compound studied, as single-, dual- and triple-receptor agonism represent pharmacologically distinct interventions.